Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort.

The combination of panobinostat, bortezomib and dexamethasone (PanBorDex) is available as a treatment option for relapsed refractory multiple myeloma (RRMM) based on the PANORAMA-1 trial which investigated this triplet in early relapse. In routine clinical care, PanBorDex is used primarily in later...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Nadjoua Maouche, Bhuvan Kishore, Zara Bhatti, Supratik Basu, Farheen Karim, Sharadha Sundararaman, Freya Collings, Bing Tseu, Heather Leary, Noel Ryman, Udaya Reddy, Grant D Vallance, Jaimal Kothari, Karthik Ramasamy
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Public Library of Science (PLoS) 2022-01-01
سلاسل:	PLoS ONE
الوصول للمادة أونلاين:	https://doi.org/10.1371/journal.pone.0270854
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!